Next-Gen Therapies: Equitable Access by 2027?

We’re creating incredible next-gen therapeutics that can actually fix diseases that were once a life sentence. But getting these treatments from a lab in a wealthy country to a patient anywhere else in the world is a logistical nightmare. The clinical trials we depend on are part of the problem, they’re often slow, expensive, and exclude the very populations that need these cures. The real challenge is making sure these breakthroughs are for everyone, not just the privileged few.

How We’re Reinventing Clinical Trials for These New Therapies

New treatments like gene therapies, cell therapies, and mRNA vaccines are a completely different beast from old-school pills. They attack diseases at their source, which means we can’t test them with the same old playbook. For rare diseases with only a handful of patients, a big randomized controlled trial is impossible, so we’re leaning more on single-arm studies or using historical data as a control group. Thankfully, regulators at the U.S. Food and Drup Administration (FDA) and the European Medicines Agency (EMA) are getting on board, because they see that these therapies require a new way of thinking.

A huge part of this shift is the move to decentralized clinical trials (DCTs), where we use tech so patients can participate from home instead of dragging themselves to a hospital. Think telemedicine check-ins, data from wearable sensors, and remote platforms becoming the norm, which is a lifesaver for patients with debilitating conditions who need the frequent monitoring that many next-gen therapies demand. The growth here is explosive. Medidata reported a 50% jump in DCT elements between 2020 and 2022. I’d expect to see another 30% increase in adoption among big pharma by 2027, simply because it’s more efficient and gets us a much wider, more representative patient pool.

DCTs aren’t a silver bullet, though. They come with major operational headaches. You have to figure out how to guarantee data integrity when it’s coming from a dozen different devices in a hundred different homes, ensure everyone has the right tech and knows how to use it, and maintain rigorous oversight when you can’t just walk down the hall to check on things. From my own work, successful DCTs depend entirely on having a rock-solid digital infrastructure and incredibly clear, standardized protocols. Without that, it’s chaos.

Regulatory Hurdles and the Push for a Global Standard

Getting a new drug to market is a marathon, and the final regulatory approval is almost always the steepest hill. With next-gen therapies, it’s even harder because their mechanisms are so new and we often have limited long-term safety data. Regulators are struggling to weigh the massive potential benefit of a cure against the unknown long-term risks, especially with gene-editing tech where we’re still worried about off-target effects.

This is why regulatory harmonization is so important for getting these drugs to people worldwide. Groups like the International Council for Harmonisation (ICH) are working on global guidelines so that the data you collect for one country is good enough for another. Their E19 guideline, for instance, helps optimize safety data collection, which saves a ton of work. When standards align, a company doesn’t have to run redundant, expensive trials just to satisfy a different regulator’s checklist. An approval from the FDA can lead to a much quicker review in the EU or Japan if the data package was built on shared ICH standards from the start.

But we’re not there yet. Major disparities still exist because every country has the final say on its own approvals, leading to a patchwork of different evidence requirements and review timelines. The EMA has its PRIME scheme and the FDA has Breakthrough Therapy designation to speed things up, but there’s no guarantee another country will honor that status. This regulatory fragmentation is a huge bottleneck. You get a drug approved in one region, but then you have to start a whole new protracted battle in the next, especially in countries with less-developed regulatory agencies. We need more mutual recognition and shared reviews if we’re serious about getting these treatments to everyone.

The Cost Is Too Damn High: Pricing and Access

Let’s be blunt: the biggest barrier to global access is cost. We’re talking millions of dollars per patient for some of these gene therapies. Take Zolgensma for spinal muscular atrophy, it’s over $2 million for a single dose. The price reflects huge R&D costs, difficult manufacturing, and the fact that it can be a one-time cure. But for that price, you’re locking out almost the entire planet, especially everyone in low and middle-income countries (LMICs).

People are trying out new pricing models to deal with this. Value-based pricing, where the payment is tied to whether the drug actually works for a patient, is getting some traction in wealthy countries. Others are trying annuity models, spreading the enormous cost over several years. But these ideas are hard to pull off. They require long-term patient tracking and data systems that just don’t exist in most LMICs. For real global equity, we need bigger ideas.

Tiered pricing is an obvious one. It’s a proven strategy where a drug’s price is set based on a country’s ability to pay. A pharmaceutical company could sell a therapy at a huge discount in an LMIC, maybe near the cost of manufacturing, to get it to people who need it. This only works with serious political will, airtight agreements to prevent the cheap drugs from being sold back to rich countries, and real transparency. This is where public-private partnerships come in. We’ve seen organizations like Gavi, the Vaccine Alliance, successfully pool demand to negotiate dirt-cheap vaccine prices. We could adapt that model for these expensive therapies, pulling together governments, philanthropies, and the industry itself. If we don’t make these kinds of deliberate interventions, these amazing new drugs will be a fantasy for billions of people.

You Can’t Just Airdrop a Cure: Building Local Capacity

Even if a drug is approved and affordable, you can’t just ship it. Delivering next-gen therapeutics requires a strong healthcare system. Cell and gene therapies in particular need specialized handling, unbreakable cold chain logistics, and doctors trained to manage them. This is a massive problem in many LMICs where even consistent electricity for refrigeration is a challenge, let alone the basics of the healthcare system. An advanced cell therapy might need a sterile lab on-site for processing and a team of experts ready to handle complex side effects, resources that are usually only found in big-city hospitals in rich countries.

If we’re serious about global access, we have to invest in building up local capacity. That means money for upgrading hospitals, setting up treatment centers, and, most importantly, training local doctors and nurses. We need partnerships between universities in high-income countries and those in LMICs to transfer skills and knowledge. We should also be looking at decentralizing manufacturing so that parts of the production process can happen closer to patients, cutting down on cost and logistical complexity. This is about fostering self-sufficiency, not just importing boxes of medicine. When local scientists are supported, they can develop their own expertise and create solutions that are better suited to their own populations. As the World Health Organization (WHO) keeps pointing out, the first step is strengthening the local regulatory agencies so they can handle these complex new products. I couldn’t agree more.

Getting a scientific breakthrough into the hands of a patient on the other side of the world is a complex mess of science, regulation, and finance. The power of next-gen therapeutics to change lives is incredible, but it won’t mean much if we don’t get the trial and distribution part right, with equity baked in from the start.